Antisense Oligonucleotides (ASOs) Targeting UBE3A

Type: gene_therapy

Status: Investigational

Developer: Roche, GeneTx Biotherapeutics (now Ultragenyx)

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026